TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. has completed the industrial and commercial registration for its registered capital alteration, following the issuance of domestic shares to target subscribers. The company’s registered capital has increased from RMB482,963,000 to RMB626,075,702, and it has obtained a renewed business license. This change reflects a significant shift in the company’s shareholding structure, with domestic shares now accounting for a larger portion of the total share capital. These amendments to the Articles of Association were authorized by the Board of Directors and do not require further approval from the general meeting, indicating streamlined governance processes.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of vaccines and related technologies. The company is based in Jiangsu Province, China, and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 31,826
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.83B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.